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ABSTRACT
Background
Resistance to triazoles was recently reported in Aspergillus fumigatus isolates cultured from
patients with invasive aspergillosis. The prevalence of azole resistance in A. fumigatus is
unknown. We investigated the prevalence and spread of azole resistance using our culture
collection that contained A. fumigatus isolates collected between 1994 and 2007.
Methods and Findings
We investigated the prevalence of itraconazole (ITZ) resistance in 1,912 clinical A. fumigatus
isolates collected from 1,219 patients in our University Medical Centre over a 14-y period. The
spread of resistance was investigated by analyzing 147 A. fumigatus isolates from 101 patients,
from 28 other medical centres in The Netherlands and 317 isolates from six other countries. The
isolates were characterized using phenotypic and molecular methods. The electronic patient
files were used to determine the underlying conditions of the patients and the presence of
invasive aspergillosis. ITZ-resistant isolates were found in 32 of 1,219 patients. All cases were
observed after 1999 with an annual prevalence of 1.7% to 6%. The ITZ-resistant isolates also
showed elevated minimum inhibitory concentrations of voriconazole, ravuconazole, and
posaconazole. A substitution of leucine 98 for histidine in the cyp51A gene, together with two
copies of a 34-bp sequence in tandem in the gene promoter (TR/L98H), was found to be the
dominant resistance mechanism. Microsatellite analysis indicated that the ITZ-resistant isolates
were genetically distinct but clustered. The ITZ-sensitive isolates were not more likely to be
responsible for invasive aspergillosis than the ITZ-resistant isolates. ITZ resistance was found in
isolates from 13 patients (12.8%) from nine other medical centres in The Netherlands, of which
69% harboured the TR/L98H substitution, and in six isolates originating from four other
countries.
Conclusions
Azole resistance has emerged in A. fumigatus and might be more prevalent than currently
acknowledged. The presence of a dominant resistance mechanism in clinical isolates suggests
that isolates with this mechanism are spreading in our environment.
The Editors’ Summary of this article follows the references.
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The saprophytic mould Aspergillus is known to cause a
spectrum of diseases in humans including allergic syndromes,
noninvasive infections, as well as invasive aspergillosis. The
morbidity and mortality associated with invasive aspergillosis
is high, although the mortality rate appears to be improving
partly because of the use of effective antifungal agents, most
notably the triazoles [1]. Voriconazole was superior to
amphotericin B for the treatment of invasive aspergillosis
and has become the primary choice to treat this condition [2].
Recently, another triazole, posaconazole, was reported to be
highly effective in preventing invasive aspergillosis in
neutropaenic patients with acute myeloid leukaemia and
myelodysplastic syndrome and in patients with graft-versus-
host-disease [3,4]. As a consequence, the role of the class of
azole compounds will further increase in the management of
invasive aspergillosis.
We recently observed the emergence of multiple-triazole-
resistance (MTR) in A. fumigatus, the primary cause of invasive
aspergillosis [5]. Patients with MTR aspergillosis presented
with primary invasive aspergillosis or with breakthrough
infection while receiving itraconazole (ITZ) or voriconazole.
The patients were from six different hospitals in The
Netherlands, and there was no evidence for spread of a
single clone [5]. The isolates were highly resistant to ITZ and
showed elevated minimum inhibitory concentrations (MICs)
of voriconazole, posaconazole, and the experimental azole
ravuconazole [5,6].
The emergence of MTR in A. fumigatus might have
signiﬁcant impact on the role of azoles in the management
of invasive aspergillosis, but the impact of resistance on the
role of azoles will greatly depend on the prevalence of MTR
and the ability to detect MTR isolates at diagnosis [7].
However, the prevalence of MTR is currently unknown,
although the number of patients with a MTR isolate was
found to be signiﬁcantly higher than in a previously
conducted surveillance study in The Netherlands [5,8]. We
investigated the prevalence of azole resistance in A. fumigatus
in a prospectively collected fungus culture collection over a
period of 14 y. We also investigated the spread of resistance
by analysing isolates in our collection, obtained from other
hospitals in The Netherlands and other countries.
Methods
Setting and Strain Selection
The Radboud University Nijmegen Medical Centre is a
tertiary care hospital with beds for 950 patients. The medical
microbiology laboratory receives specimens from patients
admitted to the hospital as well as those seen as outpatients.
The mycology unit of the laboratory has the policy to
routinely store fungal isolates from patients with fungal
diseases admitted to the hospital or seen as outpatients. For
Aspergillus species every isolate, irrespective of its clinical
signiﬁcance, was stored. In addition, fungi that were cultured
from the hospital environment or those sent to the laboratory
for identiﬁcation, in vitro susceptibility testing or as part of
research collaboration, were stored. From the isolates a spore
suspension was made in glycerol 10% and stored at  80 8C.
The fungus culture collection was searched for A. fumigatus
isolates. To investigate the prevalence of azole resistance we
used the A. fumigatus isolates that were cultured from patients
that had been admitted to our hospital or were seen as
outpatients. The spread of azole resistance was investigated
by analysing isolates that had been cultured at other hospitals
in The Netherlands and sent to our laboratory for identi-
ﬁcation. The isolates in our collection obtained from other
countries were also screened for azole resistance.
All A. fumigatus isolates were originally identiﬁed by
experienced technicians on the basis of macroscopic colony
morphology, microscopic morphology of conidia and con-
idia-forming structures, and the ability to grow at 48 8C. The
selected A. fumigatus isolates were cultured on Sabouraud
slants for 7 d and subsequently subcultured on Sabouraud
slants supplemented with itraconazole at a concentration of 8
mg/l, and incubated at 35 8C.
Phenotypic Analyses
For phenotypic comparisons, for every patient from our
hospital with an A. fumigatus isolate that grew in the presence
of 8 mg/l of itraconazole (ITZþ), two control patients were
randomly selected with an isolate that failed to grow on the
itraconazole containing slants (ITZ ): one in the 4 wk
preceding the ITZþ A. fumigatus culture date and one in the
4 wk after the culture date. In addition, one control patient
was randomly selected for every remaining month for each
year in which a patient with an ITZþ isolate was identiﬁed.
All ITZþ and ITZ  A. fumigatus control isolates were
investigated for their antifungal susceptibility of ITZ,
voriconazole, ravuconazole, posaconazole, amphotericin B,
terbinaﬁne, and caspofungin using the CLSI M38-A broth
micro-dilution reference method [9].
Genotypic Analyses
For genotypic comparisons, isolates were randomly se-
lected from the ITZ  control patients in a 1:1 ratio with the
ITZþ patients. For ITZþ and ITZ  isolates the full coding
sequence of both strands of the cyp51A gene was determined
by PCR ampliﬁcation and analysed to detect mutations [6,10].
Molecular identiﬁcation was performed by sequencing of
parts of the highly conserved b-tubulin and calmodulin gene,
as described previously [11–13], in order to rule out any
species within the Aspergillus section Fumigati, which are
closely related to A. fumigatus, but are difﬁcult to discriminate
based on morphological features alone [12]. The neighbour-
joining (NJ) method was used for phylogenetic analysis.
Sequences were compared with those of A. fumigatus, A.
lentulus, A. viridinutans, A. brevipes, A. novofumigatus, A.
fumigatiafﬁnis, and Neosartorya species all obtained from the
CBS Fungal Biodiversity Centre, Utrecht, The Netherlands
[14].
Microsatellite genotyping was used to determine the
genetic distances between the ITZþ and ITZ  A. fumigatus
isolates and analysed, as described previously [15,16]. Allele
sharing distance matrices were generated [17], and these
matrices were used as input to the Neighbor program of the
PHYLIP software package to produce the dendrograms [18].
Patient Characteristics
The electronic patient ﬁles were searched for clinical
information on the patients with an ITZ-resistant A. fumigatus
isolate and from the controls. Information collected included
the sample from which the A. fumigatus isolate was cultured,
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Azole-Resistant A. fumigatusthe underlying condition of the patients, and the presence of
invasive aspergillosis. Invasive aspergillosis was classiﬁed
according to the European Organization for Research and
Treatment of Cancer and Mycoses Study Group (EORTC)/
MSG consensus deﬁnitions [19]. Human experimentation
guidelines from the Committee on Research Involving
Human Subjects Arnhem–Nijmegen were followed in the
conduct of this research.
Statistical Analysis
To test whether ITZþisolates had been present throughout
the observation period (1994–2007), we calculated the
probability that the onset date of ﬁnding an ITZþ was as
late as we found it to be. For the phenotypic analysis we used
t-tests on the natural logarithm of the MIC’s and for the
genotypic analysis we used a Chi
2 test. For the patient
characteristics, the exact Chi
2 test was used because of the low
expected numbers in certain cells.
Results
Prevalence of ITZþ A. fumigatus Isolates
The fungal culture collection included 12,645 isolates that
had been collected between 1994 and 2007. Of these, 2,683
were identiﬁed as A. fumigatus, and 1,912 were cultured from
patients admitted to our hospital or seen as outpatients.
These isolates were cultured from 1,219 patients, with a
median number of patients of 92.5 per year (range 48 to 138),
which corresponded with a median of 130 A. fumigatus isolates
per year (range 72 to 215). All isolates were revived and
subcultured on Sabouraud slants containing 8 mg/l of ITZ at
35 8C and 1,871 isolates failed to grow under these conditions.
However, 41 isolates from 32 patients were able to grow on
the ITZ-containing agar. An ITZþ A. fumigatus isolate was
cultured for the ﬁrst time on June 15, 2000. All 674
consecutive clinical isolates from 462 patients cultured in
the 6.5 y before this date did not grow on the ITZ-containing
Sabouraud agar. From 2000 onwards, patients were observed
every year with an ITZþ A. fumigatus isolate, with a maximum
prevalence of 6.0%. Under the assumption of a random
distribution of all ITZþ isolates over the complete set of n
observations, the probability of ﬁnding the ﬁrst of k
occurrences at observation number o or later is equal to (n
  o þ 1) over k divided by n over k. For the observations at
hand this probability is so small (p , 0.001), that we can
conclude that the ITZþ isolates are not randomly distributed
over all observations: ITZþ isolates started to occur after a
given time point notably after 1994, but before or equal to
June 15, 2000 (Figure 1).
Phenotypic Analysis
For phenotypic comparisons, the ﬁrst ITZþ isolate of each
of the 32 identiﬁed patients, was compared with those of the
control group. The control group consisted of 115 patients
with one ITZ A. fumigatus isolate per patient, representing at
least one patient and isolate from every calendar month
between January 1, 2000 and December 31, 2007. The
phenotypes of the 32 ITZþ isolates and the 115 ITZ  control
isolates for the azole compounds are shown in Figure 2. All
ITZþ isolates also showed reduced susceptibility to voricona-
zole, ravuconazole, and posaconazole in comparison with the
ITZ  controls (t-test, p , 0.0005). No signiﬁcant differences
were observed for amphotericin B (t-test, p ¼ 0.892),
terbinaﬁne (t-test, p ¼ 0.591), and caspofungin (t-test, p ¼
0.816) (unpublished data).
Genotypic Analysis
For genotypic comparisons the ﬁrst ITZþ A. fumigatus
isolate from 32 patients was compared with those of 32
randomly selected control patients. The dominant genetic
changes in the ITZþ isolates in the cyp51A gene were a point
mutation at t364a, leading to the substitution of leucine 98
for histidine, together with the presence of two copies of a 34-
base pair sequence in tandem in the promoter of cyp51A gene
Figure 1. Epidemiology of ITZ Resistance in the A. fumigatus Isolates
Blue bars represent the number of patients with a positive A. fumigatus culture (left y-axis) and the red line represents the percentage of those patients
with an ITZþ isolate (right y-axis). The x-axis is the year.
doi:10.1371/journal.pmed.0050219.g001
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Azole-Resistant A. fumigatus(TR/L98H), as previously found [5]. These changes were
present in 30 of 32 (94%) ITZþ isolates and these isolates
exhibited the previously reported MTR phenotype. In one
ITZþisolate an a729g change was found to be responsible for
the substitution at codon 220 of methionine by valine
(M220V) and in the other no mutations in the cyp51A gene
were found. In all 32 A. fumigatus ITZ  control isolates, the
TR/L98H changes were not observed. To test the relation
between an ITZ resistant phenotype and the presence of TR/
L98H a Chi
2 test was performed, and there was a signiﬁcant
relation between the two factors (v
2 ¼ 50.143, df ¼ 1, p ,
0.0001). No changes were found in the cyp51A gene of control
isolates, except for three isolates, with mutations that were
not associated with a resistant phenotype.
The 64 ITZþ and ITZ  isolates could be classiﬁed as A.
fumigatus based on sequence analysis of parts of the b-tubulin
and calmodulin genes. Three clades were formed based on
the neighbour-joining (NJ) analysis of the microsatellite
typing; the ITZþ isolates were genetically different but
clustered together in a single clade (Figure 3). Four ITZþ
isolates were clustered within the ITZ  clades, two with the
TR/L98H substitution and the others with other or unknown
mutations. The branches of the ITZþ isolates had shorter
genetic distances than those within the ITZ  isolate clades.
Patient Characteristics
In 17 of 32 patients (53%), the ITZþ isolate was cultured
from a respiratory specimen (ten sputum specimens, four
bronchoalveolar lavage ﬂuids, and three bronchial secre-
tions), which was not signiﬁcantly different to 78 of 115
patients (68%) with an ITZ  isolate (41 sputum, 22
bronchoalveolar lavage ﬂuids, and 15 bronchial secretions).
A wide variety of underlying diseases and conditions were
present (Table 1), most notably patients with chronic lung
diseases or cancer. Invasive aspergillosis was diagnosed in
nine of 32 patients (28.1%) with an ITZþ isolate (three
proven, three probable, and three possible cases) compared
to 25 of 115 (21.7%) in the control group (seven proven, 12
probable, and six possible cases), which was not signiﬁcantly
different. The characteristics of the nine cases with an ITZþ
isolate are shown in Table 2.
Spread of Azole Resistance
Our culture collection contained 149 A. fumigatus isolates
from 28 other hospitals from 20 different cities in The
Netherlands. These isolates had been cultured from 101
patients with aspergillus disease and had been sent to our
laboratory between 1994 and 2006. Of these, 22 (14.5%)
isolates grew on the ITZ-containing Sabouraud slants. The
ITZþ isolates had been cultured from 13 patients (12.8%)
Figure 2. Distribution of Proportions of MICs of 32 ITZþ A. fumigatus Isolates (Blue Bars) and 115 ITZ  Controls (Red Bars) of ITZ (left upper panel),
Voriconazole (right upper panel), Ravuconazole (left lower panel), and Posaconazole (right lower panel)
Left x-axis represents the proportion of isolates and on the right x-axis the MIC distribution is shown.
doi:10.1371/journal.pmed.0050219.g002
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Azole-Resistant A. fumigatusfrom nine different hospitals from seven cities in The
Netherlands (Table 3). The ﬁrst resistant isolate was cultured
in 1998, and all others after 2000. The TR/L98H changes were
present in nine of 13 (69%) ITZþ isolates (Table 3).
Our culture collection contained 317 A. fumigatus isolates
from six European countries: Belgium, France, United King-
dom, Sweden, Norway, and Greece. These isolates had been
cultured between 1994 and 2002 as part of research
collaborations. Six isolates were resistant to itraconazole,
originating from France, Sweden, Norway, and the United
Kingdom, some of which have been reported previously
(Table 3) [6,20–22]. The isolate obtained from the United
Kingdom was originally cultured from a patient in the United
States in 1989 [22]. All azole-resistant isolates from this group
were cultured before 2000, except for the isolate from
Norway, which was the only isolate with TR/L98H (Table 3).
Discussion
Emergence of azole resistance was observed in all three sets
of A. fumigatus isolates. Besides our hospital, azole-resistant
isolates were found in nine other hospitals in The Nether-
lands, and in four other countries. The prospectively
collected isolates from our hospital indicated that resistance
had emerged since 2000 with a prevalence between 1.7% and
6%. Therefore, azole resistance in A. fumigatus is not
Figure 3. Genotypic Relatedness of 32 ITZþ A. fumigatus Isolates and 32 ITZ  Controls
The numbers are the identification numbers of the individual isolates. The ITZþ A. fumigatus with the L98H substitution and a tandem repeat in the
promoter region of the cyp51A gene are underlined and printed in red. The ITZþisolates with other or unknown resistance mechanisms are underlined
and printed in blue. The ITZ  isolates are printed in black.
doi:10.1371/journal.pmed.0050219.g003
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Azole-Resistant A. fumigatusTable 1. Classification of the Underlying Conditions in 32 Patients with an ITZþ A. fumigatus Isolate and 115 ITZ  Controls
Specialty Underlying Conditions Patients with
ITZþ Isolate (%)
Underlying Conditions Patients with
ITZ  Isolate (%)
Haematology MDS, AML (2), ALL, CML, MM, non-Hodgkin
lymphoma, CLL
8 (25) MDS (7), AML (6), ALL, CML (2), CLL (3), MM (3),
Hodgkin lymphoma, myelofibrosis, non-Hodgkin
lymphoma (4), Waldenstrom disease, aplastic anaemia,
mantel cell lymphoma
31 (26.9)
Lung diseases Cystic fibrosis (3), COPD (2) 5 (15.6) Cystic fibrosis (15), COPD (5), pneumonia, pulmonary
fibrosis, asthma (2), bronchiectasis (3)
27 (23.4)
Oncology Rhabdomyosarcoma, prostate cancer,
thyroid cancer, oropharynx cancer,
germinoma
5 (15.6) Melanoma, bladder cancer, breast cancer (3), lung
cancer (3), Bowen disease, oropharynx cancer, skin cancer
11 (9.5)
Cardiology Aumaurosis fugax, atherosclerosis, angina
pectoris, coronary artery bypass
4 (12.5) Coronary artery bypass (4), aneurysma, atherosclerosis (2) 7 (6.0)
Paediatrics Chronic granulomatous disease 2 (6.2) — 0 (0)
Gastroenterology Crohn disease 1 (3.1) Crohn disease, short bowel syndrome 2 (1.7)
Infectious diseases Pneumococcal meningitis 1 (3.1) Malaria, osteomyelitis, tuberculosis, AIDS, septicaemia 5 (4.3)
Gynaecology Cervix cancer 1 (3.1) — 0 (0)
Nephrology Kidney transplant 1 (3.1) Kidney transplant (3), tubulopathic renal disease, dialysis,
nephropathy
6 (5.2)
Surgery Pancreatitis 1 (3.1) Trauma (2), bladder surgery, pancreatitis, fracture (2),
Hernia cicatricialis, vascular, abdominal
9 (7.8)
Other Psoriasis, drug abuse, none 3 (9.4) Unknown (7), otitis externa (2), sinusitis, galactosaemia,
excema, Wegener disease, Down syndrome, CDG
syndrome, systemic lupus erythematosus, keratitis
17 (14.8)
The number of patients is given in parentheses in ‘‘Underlying Conditions’’ columns if .1.
Abbreviations: ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; CLL, chronic lymphoblastic leukaemia; CML, chronic myeloid leukaemia; COPD, chronic obstructive
pulmonary disease; MDS, myelodysplastic syndrome; MM, multiple myeloma.
doi:10.1371/journal.pmed.0050219.t001
Table 2. Clinical Characteristics of Nine Patients with Invasive Aspergillosis and an Azole-Resistant A. fumigatus Isolate
Classification
a Underlying Disease Date of
Isolation
Treatment Outcome at
Day 90
Comments
Proven Chronic granulomatous disease November 1, 2005 Caspofungin,
posaconazole
Survived Isolate was cultured at diagnosis. The patient was
on itraconazole prophylaxis for over 10 y [5].
Proven Oropharynx carcinoma August 18, 2006 Voriconazole Died The patient had been infected with an azole
susceptible and MTR isolate. The MTR isolate was
first cultured at autopsy [7].
Proven Drug abuse July 17, 2007 Caspofungin and
lobectomy
Survived The patient was previously treated with voriconazole.
Probable Kidney transplantation August 22, 2000 Amphotericin B,
itraconazole
Survived The susceptibility of the culture was not known
at the time the infection was treated.
Probable Chronic granulomatous disease April 4, 2002 Voriconazole Survived The infection developed while on itraconazole
prophylaxis and the patient was treated with high
doses of voriconazole [35].
Probable Non-Hodgkin lymphoma, alloHSCT (VUD) May 19, 2007 Voriconazole Survived The isolate was cultured from a sputum sample
obtained during voriconazole therapy.
Possible Rhabdomyosarcoma May 12, 2004 Voriconazole Survived The susceptibility of the culture was not known
at the time the infection was treated.
Possible Acute myeloid leukaemia, alloHSCT August 9, 2006 Caspofungin,
amphotericin B
Died The isolate was cultured during treatment of
invasive aspergillosis. The patient also developed
invasive scedosporiosis and zygomycosis, proven at
autopsy.
Possible Multiple myeloma, autoHSCT January 8, 2007 Itraconazole Survived The resistant isolate was cultured from a mouth
wash sample. PET-CT scan showed pulmonary
lesions consistent with invasive aspergillosis.
aAccording to the European Organization for Research and Treatment of Cancer/Mycoses Study Group consensus definitions [19].
Abbreviations: AlloHSCT, allogeneic hematopoietic stem cell transplantation; autoHSCT, autologous hematopoietic stem cell transplantation; VUD, voluntary unrelated donor.
doi:10.1371/journal.pmed.0050219.t002
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Azole-Resistant A. fumigatusuncommon and probably more widespread than currently
acknowledged.
Recently, taxonomic changes have been proposed for
Aspergillus section Fumigati, with the description of several
new species that are closely related to A. fumigatus [12]. Since
some of these new species appear to be more resistant to
antifungal compounds than A. fumigatus [23], and species
demarcation by morphologic features alone is not reliably
possible [24], we took great care to correctly identify the
species. On the basis of sequence-based analysis, we can be
conﬁdent that the observed azole resistance has emerged in A.
fumigatus.
Acquired resistance against azoles develops in response to
exposure of fungi to azole compounds. Azole resistance has
been shown to develop following exposure in the patient and
in agricultural settings [25–28]. Favourable conditions for the
development of azole resistance include long duration of
drug exposure and high numbers of reproducing micro-
organisms [29]. In patients with aspergillus disease, these
conditions are present primarily in those with cavities, such
as aspergilloma, and indeed numerous resistance mechanisms
have been described in isolates obtained from this patient
group [25–27]. Among those, changes at codon 220 have been
identiﬁed, which were also found in isolates in our study.
However, isolates that develop azole resistance during patient
therapy are unlikely to cause further transmission.
Person-to-person transmission in aspergillus disease is very
uncommon, reported only through direct donor-to-recipient
contact [30] and through infected wounds [31]. Generally, a
patient who responds to therapy overcomes the infection and
transmission of the infecting isolate is prevented. The
alternative outcome is that a patient fails to respond to
therapy, which commonly results in death. Transmission of
any isolate after death appears to be unlikely. Acquisition of
azole resistance in patients, therefore, is characterized by a
high variety of resistance mechanisms and lack of spread.
However, the pattern that we observed in the collection of
isolates from our hospital was quite different, with the
dominance of the TR/L98H resistance mechanism in clinical
isolates from epidemiologically unrelated patients. Further-
more, microsatellite typing showed that the genetic distances
between the TR/L98H isolates was shorter than for other
azole-susceptible and azole-resistant isolates. These observa-
tions suggest that the TR/L98H isolate is not transmitted from
person to person, but might be present in our environment.
The presence of Aspergillus species in the environment is
considered the most important risk factor for invasive
aspergillosis, and if TR/L98H is present in our environment
resistant conidia will be dispersed into the ambient air and
may cause infection through inhalation. A. fumigatus resistant
to medical azoles has been recovered from the environment,
indicating that this mode of transmission is feasible [32].
Furthermore, azole-resistant aspergillosis due to TR/L98H
was observed in azole-naı ¨ve patients, which supports an
environmental origin [5].
It remains unclear how azole resistance develops in A.
fumigatus in the environment. We hypothesize that resistance
in A. fumigatus could be caused by the use of azole fungicides.
Fungicides, including triazoles, are widely used for both plant
protection and material protection [33]. As A. fumigatus is a
saprophytic mould, environmental azole exposure could lead
to the development of multiple resistant mutants. The
dominance of the TR/L98H substitution is difﬁcult to explain,
but could be due to the procedure we used to select azole-
resistant isolates, to selective pressures in the environment, or
Table 3. Characteristics of Clinical A. fumigatus Isolates Present in the Fungus Culture Collection Cultured from Other Hospitals in The
Netherlands and from Other Countries
Isolate Identification
Number
Country City or
Region
a
Year of
Isolation
MIC Cyp51A Substitutions
b
ITZ VCZ PCZ AMT TER CAS TR Codon 98 Other
V12–47 US California [22] 1989 .16 1 0.5 2 0.125 0.25 — — —
3038 France Paris 1995 .16 2 2 1 0.125 0.5 — — M220R
7720 Sweden Stockholm [20] 1997 16 1 0.5 0.5 0.125 0.125 — — —
7722 Sweden Stockholm [20] 1997 .16 0.25 0.5 0.5 0.031 0.25 — — —
8327 Sweden Stockholm [20] 1998 .16 1 0.5 0.5 0.5 0.25 — — M220I
V01–70 Norway Oslo [21] 2001 .16 8 0.5 0.5 0.125 0.125 þ L98H —
V09–18 The Netherlands Groningen 1998 .16 1 0.5 0.5 0.063 0.25 þ L98H S297T, F495I
V06–31 The Netherlands Nijmegen 2001 .16 2 0.5 0.5 0.063 0.25 þ L98H —
V21–3 The Netherlands Groningen 2003 .16 2 0.5 0.5 0.125 0.25 þ L98H S297T
V28–77 The Netherlands Leeuwarden 2004 .16 0.5 0.5 1 0.063 1 — — M220I
V34–75 The Netherlands Utrecht 2004 .16 4 0.25 0.5 0.125 0.125 þ L98H —
V35–75 The Netherlands Nijmegen 2004 .16 2 0.5 0.5 0.063 0.25 — — —
V37–07 The Netherlands Utrecht 2005 .16 2 0.5 0.5 0.031 0.125 þ L98H —
V41–26 The Netherlands Zwolle 2005 .16 16 1 2 0.5 0.125 þ L98H —
V41–27 The Netherlands Zwolle 2005 8 0.5 0.125 2 0.25 0.125 — — —
V48–27 The Netherlands Rotterdam 2006 .16 8 0.5 0.5 0.031 0.125 þ L98H —
V49–09 The Netherlands Zwolle 2006 .16 8 0.5 0.5 0.031 0.25 þ L98H —
V49–29 The Netherlands Amsterdam [36] 2006 .16 16 0.25 1 0.125 0.5 þþ ——
V49–77 The Netherlands Leeuwarden 2006 .16 8 0.5 1 0.125 1 þ L98H —
aNijmegen refers to hospitals other than the Radboud University Nijmegen Medical Centre.
bTR, tandem repeat; TRþ, 34-bp tandem repeat; TRþþ, 53-bp tandem repeat.
Abbreviations: AMT, amphotericin B; CAS, caspofungin; PCZ, posaconazole; TER, terbinafine; VCZ, voriconazole.
doi:10.1371/journal.pmed.0050219.t003
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Azole-Resistant A. fumigatusto properties of these isolates that allow better survival and
spread in the environment than isolates with other mutations.
We believe that the distribution of resistance mechanisms
within the sets of isolates that we investigated, reﬂects these
two modes of resistance development (patient versus environ-
ment). Variable resistance mechanisms were dominant in the
resistant isolates from other countries, consistent with
development of resistance in individual azole-treated pa-
tients. The TR/L98H substitution was the dominant change in
the isolates cultured from our hospital, which included all A.
fumigatus isolates recovered from clinical specimens irrespec-
tive of clinical signiﬁcance, reﬂecting acquisition from the
environment. The isolates sent to us from other Dutch
hospital were exclusively from patients with aspergillus
diseases and therefore reﬂect a mixture of the two modes
of resistance development.
Our study was limited by the fact that the isolates from
other countries were not collected with the intention to study
the epidemiology of resistance. An accurate estimate of the
spread of resistance therefore could not be obtained, which
would require prospective surveillance studies. Another
limiting factor was that we were unable to reliably determine
clinical factors that might predispose for azole resistant
aspergillosis. This was beyond the primary focus of our study
and would require a prospective, multi-centre study.
Given the recent and rapid emergence of the TR/L98H
resistance mechanism in A. fumigatus, we believe that further
studies are urgently warranted. The reasons for development
of resistance and their transmission should be investigated by
sampling of the environment and, if resistance is found,
establishing a link with azole exposure. In addition, interna-
tional surveillance studies are required to determine the
prevalence and spread of TR/L98H in other countries. Our
study does indicate that the TR/L98H substitution has spread
to other countries as one isolate from Norway possessed the
TR/L98H substitution. In addition, TR/L98H isolates have
been reported from Spain [6], Belgium [34], France, and the
United Kingdom. One possible scenario might be that TR/
L98H isolates have arisen from a single source and are
subsequently spreading in the environment across countries,
which might be the beginning of the global spread in our
environment of azole resistance in A. fumigatus.
It is important to explore the clinical factors that might be
associated with the acquisition of TR/L98H isolates and
associated disease, and to determine the drug of choice for
treatment of patients with azole-resistant aspergillosis. Our
data indicate that the activity of voriconazole and posacona-
zole is reduced against the ITZ-resistant isolates compared
with the control isolates. While awaiting the results of
conﬁrmative international surveillance studies, we believe
that clinical microbiology laboratories should determine the
activity of azoles at least in those isolates that are cultured
from patients that fail to respond to azole therapy.
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Editors’ Summary
Background. Aspergillosis is a group of lung diseases caused by
infection with Aspergillus, a mold (fungus) that grows on decaying plant
matter. Because Aspergillus is widespread in the environment, people
often breathe in its spores. For most people, this is not a problem—their
immune system rapidly kills the fungal spores. However, people with
asthma or cystic fibrosis sometimes develop allergic bronchopulmonary
aspergillosis, a condition in which the spores trigger an allergic reaction
in the lungs that causes coughing, wheezing. and breathlessness. Other
people can develop an aspergilloma—a fungus ball that grows in
cavities in the lung caused by other illnesses such as tuberculosis.
However, the most serious form of aspergillosis is invasive aspergillosis.
This pneumonia-like infection, which is fatal if left untreated, affects
people who have a weakened immune system (for example, people with
leukemia) and can spread from the lungs into the heart, brain, and other
parts of the body. Aspergillosis is usually treated with triazole drugs,
which inhibit an enzyme that the fungus needs to make its cell
membranes; this enzyme is encoded by a gene called cyp51A.
Voriconazole is the first-line therapy for aspergillosis but itraconazole
and posaconazole are also sometimes used and ravuconazole is in
clinical development.
Why Was This Study Done? About half of patients with invasive
aspergillosis recover if they are given triazoles. Worryingly, however,
strains of Aspergillus fumigatus (the type of Aspergillus usually involved in
invasive aspergillosis) with resistance to several triazoles have recently
been isolated from some patients in The Netherlands. If multi-azole
resistant strains of A. fumigatus become common, they could have a
serious impact on the management of invasive aspergillosis. However,
noone knows what proportion of A. fumigatus strains isolated from
patients with aspergillosis are resistant to several azole drugs. That is,
noone knows the ‘‘prevalence’’ of multi-azole resistance. In this study,
the researchers investigate the prevalence and development of azole
resistance in A. fumigatus.
What Did the Researchers Do and Find? Since 1994, all fungal isolates
from patients at the Radboud University Nijmegen Medical Center in the
Netherlands have been stored. The researchers’ search of this collection
yielded 1,908 A. fumigatus isolates that had been collected from 1,219
patients over a 14-year period. Of these, the isolates from 32 patients
grew in the presence of itraconazole. All the itraconazole-resistant
isolates (which also had increased resistance to voriconazole, ravucona-
zole, and posaconazole) were collected after 1999; the annual prevalence
of itraconazole-resistant isolates ranged from 1.7% to 6%. The
researchers then sequenced the cyp51A gene in each resistant isolate.
Thirty had a genetic alteration represented as TR/L98H. This ‘‘dominant
resistance mechanism’’ consisted of a single amino acid change in the
cyp51A gene and an alteration in the gene’s promoter region (the region
that controls how much protein is made from a gene). The researchers
also analyzed A. fumigatus isolates from patients admitted to 28 other
hospitals in the Netherlands. Itraconazole resistance was present in
isolates from 13 patients (out of 101 patients) from nine hospitals; the
TR/L98H genetic alteration was present in 69% of the itraconazole-
resistant isolates. Finally, itraconazole resistance was present in six
isolates from four other countries (out of 317 isolates from six countries);
only one Norwegian isolate had the TR/L98H genetic alteration.
What Do These Findings Mean? These findings indicate that azole
resistance is emerging in A. fumigatus and may already be more
prevalent than generally thought. Given the dominance of the TR/L98H
genetic alteration in the azole-resistant clinical isolates, the researchers
suggest that A. fumigatus isolates harboring this alteration might be
present and spreading in the environment rather than being selected for
during azole treatment of patients. Why azole resistance should develop
in A. fumigatus in the environment is unclear but might be caused by the
use of azole-containing fungicides. Further studies are now urgently
needed to find out if this is the case, to measure the international
prevalence and spread of A. fumigatus isolates harboring the TR/L98H
genetic alteration, and, most importantly, to develop alternative treat-
ments for patients with azole-resistant aspergillosis.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050219.
  The MedlinePlus Medical Encyclopedia has a page on aspergillosis (in
English and Spanish)
  The UK National Health Service Direct health encyclopedia has
detailed information about all aspects of aspergillosis
  The US Centers for Disease Control and Prevention also has
information about aspergillosis
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